Individuals with OCD or TS were recruited for a multi-center collaborative genome-wide analyses (GWAS, described in18 and19). Participants ages 18 and older provided written, voluntary informed consent for participation in genetic studies. Individuals under age 18 provided assent; written parental consent was also obtained. The study was approved by the Ethics Committees of all participating sites. Recruitment sites varied in screening and exclusions related to other neurodevelopmental disorders; see supplementary tables S9, S10, S11, available online, for available clinical information regarding ID, ASD, ADHD, and seizures. OCD and TS samples were collected independently but were genotyped jointly to facilitate cross-disorder analyses. All cases were genotyped on the Illumina Human610-Quadv1_B platform.
